This is it? GSK rolls out a buzzy new R&D plan long on as­pi­ra­tions and short on per­for­mance goals

Glax­o­SmithK­line set out to kick­start some en­thu­si­asm for its pipeline this morn­ing. But CEO Em­ma Walm­s­ley and her new R&D chief Hal Bar­ron clear­ly have a lot more work cut out for them on that crit­i­cal point.

Its quar­ter­ly re­port high­lights a strat­e­gy in R&D that will be heav­i­ly fo­cused on the im­mune sys­tem and hu­man ge­net­ics — two well es­tab­lished fields that long ago at­tract­ed the at­ten­tion of just about every­one work­ing in drug de­vel­op­ment these days. And they signed up 23andMe — pay­ing $300 mil­lion to buy in and gain ex­clu­sive ac­cess to its da­ta base — to help ex­plore dis­ease rel­e­vant genes, herald­ing a “ma­jor ad­vance” while adding to a slate of al­liances on ge­net­ics the Lon­don-based gi­ant has al­ready com­plet­ed.

The phar­ma gi­ant says it will fo­cus more on CRISPR tech, with an em­pha­sis on ma­chine learn­ing and com­pu­ta­tion­al de­sign — a cou­ple of buzzy fea­tures that have al­so been mak­ing the rounds late­ly.

There’s a com­ment on cul­ture:

GSK al­so in­tends to pro­mote a cul­ture of in­creased ac­count­abil­i­ty and smart risk-tak­ing. This will in­clude re­defin­ing suc­cess and fos­ter­ing a cul­ture of truth-seek­ing ver­sus pro­gres­sion- seek­ing, and op­ti­mised port­fo­lio de­ci­sion-mak­ing, along­side im­ple­men­ta­tion of a new ro­bust gov­er­nance mod­el. Tar­get­ed busi­ness de­vel­op­ment to strength­en the Group’s pipeline and tech­nol­o­gy ca­pa­bil­i­ties will al­so be part of the new R&D ap­proach. 

And then there’s the po­ten­tial. Look­ing to make a come­back in phar­ma R&D, GSK tout­ed a BC­MA ther­a­py in de­vel­op­ment — hard­ly the first. HIV al­so war­rants a men­tion, though that will be cen­tered in its ma­jor­i­ty-owned sub­sidiary Vi­iV,  which has been mak­ing sig­nif­i­cant ad­vances along­side the vac­cines group.

With lit­tle in the way of specifics to of­fer from the phar­ma side in the near term, GSK is vague­ly promis­ing big things be­yond 2020.

In a con­fer­ence call with re­porters to­day — at least the ones that weren’t al­lowed a pre­view — Bar­ron and 23andMe chief Anne Wo­j­ci­c­ki hit the dis­cov­ery an­gle hard, high­light­ing what they see as an op­por­tu­ni­ty to find gene vari­ants for Parkin­son’s and can­cer and oth­er dis­eases that would make good new pro­grams.

I asked Bar­ron for his as­sess­ment of the R&D op­er­a­tion he had tak­en on. He em­pha­sized the pos­i­tive, but al­so ac­knowl­edged the weak­ness­es.

“I think it’s im­por­tant to look back at what GSK has done well,” he replied. There have been a num­ber of new ap­provals, he said, but with­out the kind of com­mer­cial im­pact that can gen­er­ate the num­bers the com­pa­ny needs. This new al­liance with 23andMe, he said, of­fered the chance to get at that — with new tar­gets that could be suit­able for mul­ti­ple ap­provals and bet­ter life cy­cle man­age­ment of im­por­tant new drugs.

I tried to fol­low up with a ques­tion on whether GSK had a dis­cov­ery or late-stage drug prob­lem, but got cut off on the call.

GSK brought in the leg­endary Genen­tech vet to turn around what is per­haps the slow­est, most woe­ful Big Phar­ma R&D group in the world. A ge­net­ics data­base deal with 23andMe will of­fer no short-term help, of­fer­ing a leg up for dis­cov­ery work that will be years in the mak­ing. And Bar­ron will try to or­ches­trate the turn­around from his base in the Bay Area, far from GSK’s cen­tral re­search op­er­a­tions around Philadel­phia and Steve­nage in the UK.

De­spite a bud­get of $6 bil­lion, Glax­o­SmithK­line has had lit­tle in the late-stage pipeline to boast about — and the late-stage pipeline is what is used to judge a com­pa­ny’s po­ten­tial in turn­ing out block­busters.

GSK’s phar­ma R&D group doesn’t make block­busters, though. Or hasn’t in years. And adopt­ing a strat­e­gy that any busi­ness school grad­u­ate could have whipped up one af­ter­noon won’t gin up miss­ing ex­cite­ment in the in­vest­ment com­mu­ni­ty.


Im­age: Hal Bar­ron. GSK

Rupert Vessey, Bristol Myers Squibb head of research and early development

Up­dat­ed: R&D tur­bu­lence at Bris­tol My­ers now in­cludes the end of a $650M al­liance and the de­par­ture of a top re­search cham­pi­on

This morning biotech Dragonfly put out word that Bristol Myers Squibb has handed back all rights to its IL-12 clinical-stage drug after spending $650 million to advance it into the clinic.

The news arrives amid a turbulent R&D stage for the pharma giant, which late last week highlighted Rupert Vessey’s decision to depart this summer as head of early-stage R&D following a crucial three-year stretch after he jumped to Bristol Myers in the big Celgene buyout. During that time he struck a series of deals for Bristol Myers, and also shepherded a number of Celgene programs down the pipeline, playing a major role for a lineup of biotechs which depended on him to champion their drugs.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Illustration: Assistant Editor Kathy Wong for Endpoints News

How Pur­due's $272M ad­dic­tion pay­out fund­ed a new home for its dis­card­ed non-opi­oid re­search

Don Kyle spent more than 20 years working for Purdue Pharma, right through the US opioid epidemic that led to the company’s rise and eventual infamy. But contrary to Purdue’s focus on OxyContin, Kyle was researching non-opioid painkillers — that is, until the company shelved his research.

As the company’s legal troubles mounted, Kyle found an unlikely way to reboot the project. In 2019, he took his work to an Oklahoma State University center that’s slated to receive more than two-thirds of the state’s $272 million settlement with Purdue over claims that the drugmaker’s behavior ignited the epidemic of opioid use and abuse.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bill Haney, Dragonfly CEO (Dave Pedley/Getty Images for SXSW)

Drag­on­fly chief: Bris­tol My­ers shouldn’t blame IL-12’s clin­i­cal per­for­mance for de­ci­sion to scrap the deal — eco­nom­ics played a key role

Bristol Myers Squibb says the IL-12 drug they were developing out of Dragonfly Therapeutics was scrubbed from the pipeline for a simple reason: It didn’t measure up on clinical performance.

But Bill Haney, the CEO of Dragonfly, is taking issue with that.

The early-stage drug, still in Phase I development, has passed muster with Bristol Myers’ general clinical expectations, advancing successfully while still in Phase I, he says.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

President Joe Biden at the State of the Union address with Vice President Kamala Harris and House Speaker Kevin McCarthy (Patrick Semansky/AP Images)

The drug pric­ing pres­i­dent: Biden warns of ve­to for any IRA re­peal at­tempts

President Joe Biden made clear in his “finish the job” State of the Union address last night that one of those jobs to be finished is insulin prices.

Biden’s push again to tackle insulin prices, after Republicans rebuffed the idea last summer and just after Biden won Medicare drug price negotiations/caps via the Inflation Reduction Act, shows how heavily he’s leaning into this work.

Utpal Koppikar, new Verily CFO

Ex­clu­sive: Ver­i­ly wel­comes Atara Bio­ther­a­peu­tics vet­er­an as new CFO

Verily, Alphabet’s life sciences outfit, has plucked a new CFO from the ranks of Atara Biotherapeutics, the company announced on Wednesday.

Utpal Koppikar joins Verily after a nearly five-year stint as CFO and senior VP at Atara, though his résumé also boasts roles at Gilead and Amgen.

The news follows a major reshuffling at Verily, including several senior departures earlier this year and a round of layoffs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Singer Nick Jonas is back at work for Dexcom, this time for its new G7 glucose monitor.

Dex­com's spokescelebri­ty Nick Jonas re­turns to Su­per Bowl in new glu­cose mon­i­tor com­mer­cial

Dexcom is going back to the Super Bowl with its pop singer and patient spokesperson Nick Jonas. Jonas takes center stage as the lone figure in the 30-second commercial showcasing Dexcom’s next-generation G7 continuous glucose monitoring (CGM) device.

Jonas’ sleight-of-hand tricks populate the commercial — he pinches his empty fingers together and pops them open to reveal the small CGM — even as he ends the ad, saying, “It’s not magic. It just feels that way.” Jonas then disappears in a puff of smoke.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Richard Francis, newly-appointed Teva CEO (Novartis via Facebook)

New Te­va CEO Richard Fran­cis repri­or­i­tizes to 'get back to growth'

Six weeks into his new role at the helm of Teva Pharmaceutical, Richard Francis said it’s time to “get back to growth,” starting with a good look at the company’s priorities.

The chief executive has kicked off a strategic review, he announced during Teva’s quarterly call, which will continue over the next several months and produce results sometime in the middle of 2023. That means some pipeline cuts may be in store, he told Endpoints News, while declining to offer much more detail.

FDA Commissioner Robert Califf on Capitol Hill, Feb. 8, 2023 (Drew Angerer/Getty Images)

FDA com­mis­sion­er floats ideas on how to bet­ter han­dle the pan­dem­ic

FDA Commissioner Rob Califf joined the heads of the CDC and NIH in the hot seat today before a key House subcommittee, explaining that there needs to be a much faster, more coordinated way to oversee vaccine safety, and that foreign biopharma inspections, halted for years due to the pandemic, are slowly ramping up again.

Califf, who stressed to the House Energy and Commerce’s Subcommittee on Health that the CDC also needs better data, made clear that the FDA’s ability to monitor the safety of vaccines “would also benefit greatly by a coordinated federal public health data reporting authority.”

Sanofi is renewing its #VaccinesForDreams campaign with more stories, such as Juan's in Argentina (Sanofi)

Sanofi re­news so­cial cam­paign to re­mind that vac­cines let peo­ple ‘Dream Big’

Sanofi is highlighting people’s dreams — both big and small — to make the point that vaccines make them possible.

The renewed “Dream Big” global social media campaign’s newest dreamer is Juan, a teacher in the Misiones rainforest in Argentina whose story is told through videos on Instagram and Sanofi’s website with the hashtag #VaccinesForDreams.

The campaign ties to Sanofi’s broader umbrella initiative “Vaccine Stories” to promote the value of vaccines and drive awareness of the need for improved vaccination coverage.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.